Monoclonal antibody · Antagonist of Interleukin-4 receptor alpha subunit (IL4R) · developed by Regeneron Pharmaceuticals
Dupilumab is a human IgG4 monoclonal antibody that binds the IL-4 receptor alpha subunit, blocking signaling by both IL-4 and IL-13. It is studied in atopic dermatitis and asthma, and is used in several other type 2 inflammatory conditions.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 22, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05268107 | Phase 4 | Atopic Dermatitis | Recruiting | REGN |
| NCT07919899 | Phase 3 | Dermatitis Atopic | Not yet recruiting | SNY |
| NCT07309614 | Phase 3 | Asthma Control | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Asthma ControlAtopic DermatitisDermatitis Atopic
Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →